



Strategy and Sustainability Division
MINISTRY FOR HEALTH, THE ELDERLY AND COMMUNITY CARE

DH CIRCULAR No.108/2011

DH 2126/2011

10th May, 2011

Attention all Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Pregabalin 75mg, 150mg and 300mg capsules

Pregabalin has been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for introduction into the Government Formulary List.

Pregabalin, is protocol-regulated and the protocol number is 160. Consultant Neurologists, Consultant Psychiatrists and Consultant Geriatricians can prescribe Pregabalin 75mg, 150mg and 300mg capsules, for adult patients suffering from (i) Epilepsy – partial seizures with or without secondary generalisation, and (ii) Trigeminal Neuralgia – neuropathic pain, as per attached protocol.

Pregabalin will in greater part replace gabapentin on the formulary. A small supply of gabapentin is to be retained on the formulary for paediatric patients aged 6 years and above and adolescent patients (12-17 years) suffering from epilepsy and for exceptional cases.

Patients currently approved for gabapentin as per exceptional treatment policy, will upon expiry of their approval be referred to the relevant consultants in order to be transferred on pregabalin or otherwise.

Pregabalin 75mg, 150mg and 300mg capsules have been procured through GHPS and are now available for use as per protocol.

Thank you

For your attention, please

Dr Natasha Azzopardi Muscat
Director General

“PALAZZO CASTELLANIA” 15, MERCHANTS STREET, VALLETTA, VLT 03

Tel. Nos. +00356 21224071/ 2299 2232

Fax no. +00356 2299 2663

e-mail: dgss.mhec@gov.mt

Pregabalin 75mg, 150mg and 300mg Capsules

Prescriber Criteria: Consultant Neurologist
Consultant Psychiatrist
Consultant Geriatrician

Out-patient and In-patient use:

1. Epilepsy
2. Trigeminal Neuralgia

To be used for adult patients with:

- Partial seizures with or without secondary generalization
- Neuropathic pain due to trigeminal neuralgia

Duration of approval:

1 year